Floatz logo

ATENOLOL

Stroke Disorder

Northern California Institute of Research and EducationSmall moleculePhase 4 / ApprovedActive
BBB
75/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
61/ 100
Competitive Position
95/ 100

Competitive context

127 Active assets in the Stroke Disorder cohort.

Asset / SponsorPhaseRating
INCOBOTULINUMTOXINA
Parc de Salut Mar
Phase 4BBB
Aggrenox
Boehringer Ingelheim
Phase 4BBB
Dextromethorphan
University of Florida
Phase 4BBB
Tenecteplase
Assistance Publique - Hôpitaux de Paris
Phase 4BBB
Nerinetide
NoNO Inc.
Phase 3BBB

View all 50 →

Same molecule, other indications

ATENOLOL is also rated in:

myocardial ischemiaDormant
BBB
Indicative · Phase 4
75 / 100
View asset →
hypertensive disorderDormant
BB
Indicative · Phase 4
71 / 100
View asset →
diabetes mellitusDormant
BB
Indicative · Phase 4
68 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →